* Company receives final FDA confirmation to initiate phase 3 studies using next generation inopulse device
The post BRIEF-Bellerophon Therapeutics Inc receives final FDA confirmation to initiate Phase 3 studies using next generation inopulse device appeared first on NASDAQ.